Antibody Against an Alzheimer’s Associate Protein Presented at the 2015 Society for Neuroscience ConferenceAntibody Update 1

At the Society for Neuroscience (SfN) conference in Chicago, an abstract was presented by a Harvard research team about an antibody to Alzheimer’s associated protein pGlu -3 abeta. pGlu-3 abeta is a protein that is found in large quantities in the brains of Alzheimer’s patients, and is associated with abeta plaque build-up; a strong possibile cause of Alzheimer’s. Vaccination of 16-month-old APP/PS1 dE9 mice with anti-pGlu-3 abeta isotype IgG2a functional antibodies showed a significant reduction in the quantity of the pGlu-3 abeta in the brain, as well as a decrease in abeta plaque buildup. These results also showed a positive effect on the subjects’ cognitive performance in memory tests, indicating relief from Alzheimer’s like symptoms.


Green Sea Turtles Have Asymmetrical IgY Antibodies With New Immunochemistry

Antibody Update 2

The Journal of Immunology published a paper showing that green sea turtles have 2 forms of asymmetrical IgY antibodies, differing from more common symmetrical IgG and IgY immunoglobulins. 3 reptilian IgY antibodies were studied: a 5.7S 120-kDa, a 7S 200-kDa, and a 7S 90-kDa. Both molecules of the 7S variety were made up of 2 different sized heavy chains. These asymmetrical 7S IgY’s were also found in higher concentration than the 5.7S variety when exposed to certain antigens. Moreover, the 7S 90-kDa IgY was found in a higher concentration than the larger asymmetrical IgY after repeated exposure to the same antigen, indicating a different immunochemistry between all 3 molecules. Study of these turtles immunology will lend new insight into the evolution of the immune system and possibly yield new advances in the field.

FDA Approves the First Virus Based Treatment of Cancer

Antibody Update 3

Nature published an article saying the United States FDA has approved the first genetically engineered virus designed for the treatment of cancer. The T-VEC virus was engineered from a strain of the herpes simplex virus initially, and was designed to lyse malignant cancer cells. Once lysed, antigens found inside the malignant cells are vulnerable for the immune system to target. The immune system is then able to begin cloning the necessary antibodies for attacking cancerous cells. This is the first treatment using an engineered virus approved by the FDA, and could be a promising breakthrough in the treatment of cancer or even other diseases.  

The Antibody Engineering and Therapeutics Conference is Next Month! 

ProSci will be attending The Antibody Engineering and Therapeutics conference from Dec. 7th to Dec. 10th in sunny San Diego to present our custom antibody services and a new abstract from our research team. Keep up on the latest updates on the conference using #AntibodyEng, and look out for ProSci on Facebook, Twitter, and LinkedIn for the most exciting news!

Antibody Update 4